Helicobacter pylori-Related Metabolic Parameters and Premalignant Gastric Mucosa Histological Lesions in Swiss Bariatric Patients
- PMID: 34201748
- PMCID: PMC8303942
- DOI: 10.3390/microorganisms9071361
Helicobacter pylori-Related Metabolic Parameters and Premalignant Gastric Mucosa Histological Lesions in Swiss Bariatric Patients
Abstract
Obesity, as a major risk factor of metabolic syndrome (MetS), represents a pandemic, especially in Western societies, and is considered a risk factor for malignancies. Helicobacter pylori (Hp), is a definite carcinogen with global distribution. We aimed to investigate, for the first time in Switzerland, the main gastric mucosa premalignant histological lesions of bariatric patients in correlation with MetS components and Hp Infection (Hp-I). By reviewing retrospectively 94304 patient cases, a total of 116 eligible patients having undergone bariatric surgery were identified. The mean patient age was 48.66 years. Hp(+) patients were 24% (28/116). Presence of gastric mucosa atrophy was documented in 8/28 Hp(+) patients (29%) and (2/88) Hp(-) ones (2%) (p = 0.006). Gastric mucosa intestinal metaplasia was observed in 14/28 (50%) Hp(+) patients versus 3/88 (3.4%) of Hp(-) group (p < 0.0001). Hp(+) patients exhibited statistically higher arterial hypertension (p = 0.033). The homeostatic model of assessment insulin resistance was also statistically significantly higher for the Hp(+) group (p < 0.001). In a multivariate analysis, including arterial hypertension, gastric mucosa atrophy, and intestinal metaplasia as variables, statistical significance remained only for intestinal metaplasia (p = 0.001). In conclusion, Hp-I is associated with premalignant gastric mucosa histologic lesions and MetS components, including arterial hypertension and IR. Further large-scale prospective studies are required to confirm these findings.
Keywords: GA; Helicobacter pylori; Hp; IME; MetS; bariatric; gastric atrophy; intestinal metaplasia; metabolic syndrome.
Conflict of interest statement
Doulberis received travel grants from Gilead Sciences Switzerland Sàrl. Kuntzen received travel grants from Gilead Sciences, Vifor, Roche, Merck, Sharp & Dohme and Amgen, and Research grants from the Novartis Stiftung für klinische Forschung, and Merck, Sharp & Dohme. All other authors declare no conflict of interest.
Figures
References
-
- Doulberis M., Polyzos S.A., Papaefthymiou A., Katsinelos P., Kiosses C., Kountouras J. Treatment of nonalcoholic fatty liver disease: From adult trials to perspectives in the management of children and adolescents. Expert Opin. Pharmacother. 2020;21:247–251. doi: 10.1080/14656566.2019.1702967. - DOI - PubMed
-
- Kountouras J., Polyzos S.A., Katsinelos P., Zeglinas C., Artemaki F., Tzivras D., Vardaka E., Gavalas E., Romiopoulos I., Simeonidou C., et al. Cardio-cerebrovascular disease and Helicobacter pylori-related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. Int. J. Cardiol. 2017;229:17–18. doi: 10.1016/j.ijcard.2016.11.265. - DOI - PubMed
-
- Komaei I., Currò G., Mento F., Cassaro G., Lazzara C., Barbera A., Ammendola M., Alibrandi A., Navarra G. Gastric Histopathologic Findings in South Italian Morbidly Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy: Is Histopathologic Examination of All Resected Gastric Specimens Necessary? Obes. Surg. 2020;30:1339–1346. doi: 10.1007/s11695-019-04272-x. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
